Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials Silvina Gallo Roberto A. Calle Steven G. Terra Annpey Pong Lisa Tarasenko Annaswamy Raji 10.6084/m9.figshare.12481244.v1 https://adisjournals.figshare.com/articles/figure/Effects_of_Ertugliflozin_on_Liver_Enzymes_in_Patients_with_Type_2_Diabetes_A_Post-Hoc_Pooled_Analysis_of_Phase_3_Trials/12481244 <p>The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).<br></p> <p>© The authors, CC-BY-NC 2020.<b> </b></p> 2020-06-29 09:57:34 Alanine aminotransferase Aspartate aminotransferase Body weight Ertugliflozin Fibrosis-4 index HbA1c Liver enzymes SGLT2 inhibitor Type 2 diabetes mellitus